Simplex Trading
ELVN icon

Simplex Trading’s Enliven Therapeutics ELVN Stock Holding History

Simplex Trading’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.1K Sell
456
-7,427
-94% -$315K ﹤0.01% 6975
2026
Q1 		$309K Buy
7,883
+5,234
+198% +$145K ﹤0.01% 3797
2025
Q4 		$40.8K Buy
2,649
+2,480
+1,467% +$49.4K ﹤0.01% 5845
2025
Q3 		$3K Sell
169
-14
-8% -$282 ﹤0.01% 8494
2025
Q2 		$3K Buy
183
+133
+266% +$2.52K ﹤0.01% 7955
2025
Q1 		$0 Buy
+50
New +$1.08K ﹤0.01% 8763
2024
Q3 		– Sell
-93
Closed -$2K – 8746
2024
Q2 		$2K Buy
+93
New +$1.96K ﹤0.01% 8255
2022
Q2 		– Sell
-84
Closed -$411 – 10199
2022
Q1 		$0 Buy
84
+9
+12% +$59 ﹤0.01% 10616
2021
Q4 		$0 Buy
+75
New +$983 ﹤0.01% 10692

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Simplex Trading's ELVN Position: Q2 2026 in Review

Simplex Trading reduced its Enliven Therapeutics (ELVN) stake by 94% in Q2 2026, selling an estimated $315K and leaving 456 shares worth $23.1K. The position accounts for ﹤0.01% of the portfolio, ranked #6975.

Simplex Trading first reported a position in ELVN in Q4 2021 and has held it in 9 quarters since. The position peaked at $309K in Q1 2026. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Simplex Trading held 456 shares of Enliven Therapeutics worth $23.1K as of Q2 2026.
  • Simplex Trading sold 7,427 Enliven Therapeutics shares in Q2 2026, an estimated $315K.
  • Enliven Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #6975 holding.
  • Simplex Trading first reported a position in Enliven Therapeutics in Q4 2021 and has held it in 9 quarters since.
  • Simplex Trading's Enliven Therapeutics position peaked at $309K in Q1 2026.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.